<table>
<thead>
<tr>
<th>Arizona</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AZ H 2310</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Title:</strong> Biological Products</td>
<td></td>
</tr>
<tr>
<td><strong>Summary:</strong> Relates to biological products; relates to prescription orders; provides conditions to allow a pharmacist to substitute a biological product for a prescribed biological product; requires the pharmacy to retain a record of the biological product dispensed; requires the board to maintain on its public website, a link to the current list of each biological product determined by the United States Food and Drug Administration to be an interchangeable biological product.</td>
<td></td>
</tr>
<tr>
<td><strong>Disposition:</strong> Pending</td>
<td></td>
</tr>
<tr>
<td><strong>Introduced:</strong> 01/14/2016</td>
<td></td>
</tr>
<tr>
<td><strong>Status:</strong> 03/24/2016 SENATE Engrossed. Printed. 03/24/2016 In SENATE. Read third time. Passed SENATE. *****To HOUSE for concurrence. (29-0)</td>
<td></td>
</tr>
<tr>
<td><strong>Commentary:</strong> H 2310 ensures that pharmacists communicate &quot;&quot; to a patient's prescribing physician &quot;&quot; any and all dispensations of a substitute biological product for another biologic drug. NORD supports this bill and submitted written testimony.</td>
<td></td>
</tr>
<tr>
<td><strong>Author:</strong> Cobb (R)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>California</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CA A 2400</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Title:</strong> Prescription Drug Coverage: Prior Authorization</td>
<td></td>
</tr>
<tr>
<td><strong>Summary:</strong> Specifies that an external exception request may be file in lieu of a grievance with a health care service plan or health insurer regarding nonformulary drugs, following an adverse benefit determination. Requires any plan or insurer grievance system process or a plan or insurer internal process to require the resolution of grievances or complaints that involve the disapproval of a request for a formulary drug within a specified time period for both nonurgent and exigent circumstances.</td>
<td></td>
</tr>
<tr>
<td><strong>Disposition:</strong> Pending</td>
<td></td>
</tr>
</tbody>
</table>
CA S 1095

Title: Newborn Screening Program
Summary: Requires the State Department of Public Health to expand statewide screening of newborns to include screening for any disease as soon as the disease is adopted by the federal Recommended Uniform Screening Panel.
Disposition: Pending
Introduced: 02/17/2016
Status: 04/13/2016 From SENATE Committee on HEALTH: Do pass to Committee on APPROPRIATIONS. (9-0)
Commentary: NORD supports SB 1095 and submitted written testimony to the Senate Health Committee
Author: Pan (D)

Connecticut

CT H 5132

Title: Newborn Screening for Pompe Disease
Summary: Adds Pompe disease to the list of testing to be administered to newborn infants.
Disposition: Failed
Introduced: 02/09/2016
Status: 03/23/2016 Failed Joint Favorable deadline.
Commentary: NORD supports this bill and submitted written testimony.
Introducer: Joint Committee on Public Health

CT H 5517

Title: Cost Sharing for Prescription Drugs
Summary: Concerns cost-sharing for prescription drugs; limits coinsurance, copayments, deductibles or other out-of-pocket expenses imposed on insureds for prescription drugs.
Disposition: Failed
Introduced: 03/02/2016
Status: 03/17/2016 Failed Joint Favorable deadline.
Commentary: NORD is part of a CT-based coalition supporting this bill and provided in-person and written testimony.
Introducer: Joint Committee on Insurance and Real Estate

CT S 313
**Title:** Biological Products  
**Summary:** Relates to biological products and interchangeable biological products; provides for the definitions of biological product and interchangeable; provides that, except under certain circumstances or unless the purchaser instructs otherwise, the pharmacist may substitute a biological product for a prescribed biological product if certain conditions exist; requires pharmacists to inform patients of the substitution; provides for related signage and certain related recordkeeping and maintenance requirements.  
**Disposition:** Pending  
**Introduced:** 02/25/2016  
**Status:** 03/24/2016 Reported out of Legislative Commissioner's Office.  
03/24/2016 Senate Calendar No. 188.  
03/24/2016 Reissued by Legislative Commissioner's Office with File No. 218.  
**Commentary:** Sb 313 ensures that pharmacists communicate ""to a patient's prescribing physician "" any and all dispensations of a substitute biological product for another biologic drug. NORD supports this bill and submitted written testimony.  
**Introducer:** Joint Committee on General Law

### District of Columbia

**DC B 32**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Specialty Drug Copayment Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary:</strong></td>
<td>(Permanent Law) Imposes a limit on the amount that a person must pay in copayment or coinsurance through a health benefit plan for a prescription for a specialty drug.</td>
</tr>
<tr>
<td><strong>Disposition:</strong></td>
<td>Pending</td>
</tr>
<tr>
<td><strong>Introduced:</strong></td>
<td>01/20/2015</td>
</tr>
<tr>
<td><strong>Status:</strong></td>
<td>10/28/2015 Public Hearing held.</td>
</tr>
<tr>
<td><strong>Sponsor:</strong></td>
<td>Cheh (D)</td>
</tr>
</tbody>
</table>

**DC B 142**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Medical Foods Insurance Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary:</strong></td>
<td>(Permanent Law) Establishes a law requiring health insurance policies to provide coverage for certain medical foods.</td>
</tr>
<tr>
<td><strong>Disposition:</strong></td>
<td>Pending</td>
</tr>
<tr>
<td><strong>Introduced:</strong></td>
<td>03/17/2015</td>
</tr>
</tbody>
</table>
| **Status:** | 03/17/2015 INTRODUCED.  
03/17/2015 To COUNCIL Committee on BUSINESS, CONSUMER, AND REGULATORY AFFAIRS. |
| **Sponsor:** | Evans (D) |

### Delaware

**DE S 58**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Newborn Screening Program</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary:</strong></td>
<td>Creates the Newborn Screening Program; provides screening for metabolic, hematologic, endocrinologic, immunologic and structural</td>
</tr>
</tbody>
</table>
disorders; relates to blood specimens and consent; clarifies that genetic information may be retained for a specified time; establishes a Newborn Screening Advisory Committee; provides for confidentiality of test results; requires parental and physician notification; provides for billing; provides that no newborn shall be denied testing because of parental inability to pay.

**Disposition:** Enacted
**Introduced:** 04/15/2015
**Status:** 07/15/2015 Signed by GOVERNOR. 07/15/2015 Chapter Number 96

**Primary Sponsor:** Hall-Long (D)

---

**Georgia**

**GA H 875**

**Title:** Health Benefit Policies Information and Processes
**Summary:** Relates to insurance generally; requires issuers of health benefit policies provide certain information to enrollees and establish certain processes and limits relating to specialty drugs; provides for a short title; defines terms; provides specific requirements for issuers; provides for related matters; repeals conflicting laws.

**Disposition:** Failed - Adjourned
**Introduced:** 01/28/2016
**Status:** 02/02/2016 In HOUSE: Read 2nd time.

**Author:** Hawkins (R)

---

**Hawaii**

**HI H 254**

**State ID** SD1
**Title:** Biosimilars Working Group
**Summary:** Relates to medicines; allows for the regulation of biosimilar medicines to ensure patient safety and access to medicines at lower prices; repeals the drug product selection board and transfer the board's duties of creating the list of substitutable generic drug products and biological products to the director of health.

**Disposition:** Pending
**Introduced:** 01/22/2015
**Status:** 04/14/2016 In HOUSE. HOUSE disagreed to SENATE amendments.
**Commentary:** H 254 ensures that pharmacists communicate "" to a patient's prescribing physician "" any and all dispensations of a substitute biological product for another biologic drug. NORD supports this bill and submitted written testimony.

**Author:** Evans (D)

---

**HI HR 76**

**Title:** Statewide Rare Disease Task Force
**Summary:** Requests the convening of a statewide rare disease task force.

**Disposition:** Pending

**Introduced:** 03/11/2016

**Status:** 03/14/2016 To HOUSE Committee on HEALTH.
03/14/2016 Subsequent referral set for: HOUSE Committee on FINANCE.

**Commentary:** NORD supported the creation of a Rare Disease Task Force as part of its Rare Disease Day event in Hawaii.

**Author:** Kong (D)

### Iowa

<table>
<thead>
<tr>
<th>Bill Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IA H 14</strong></td>
<td>Screening of Newborns for Lysosomal Storage Disorders</td>
</tr>
</tbody>
</table>

**Summary:** Directs the Center for Congenital and Inherited Disorders with the assistance of the Department of Public Health to adopt rules to require the screening of newborns for the six specified lysosomal storage disorders as part of the newborn metabolic screening; provides that the LSDs specified are: Globoid cell leukodystrophy, Fabry, Pompe, Niemann-Pick, Gaucher, and Hurler syndrome.

**Disposition:** Pending - Carryover

**Introduced:** 01/15/2015

**Status:** 01/20/2015 In HOUSE Committee on HUMAN RESOURCES: Subcommittee assignments: Forristall, Bacon, and Wessel-Kroeschell.

**Author:** Ruff (D)

### Illinois

<table>
<thead>
<tr>
<th>Bill Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IL H 2790</strong></td>
<td>Newborn Metabolic Screening Act</td>
</tr>
</tbody>
</table>

**Summary:** Amends the Newborn Metabolic Screening Act; requires the Department of Public Health to provide all newborns with screening tests for the presence of adrenoleukodystrophy; provides that testing shall begin within a certain number of months following the occurrence of various events, including the development and validation of a reliable methodology, the availability of any necessary reagents, and the establishment of relevant performance specifications; specifies a base fee for newborn screening services.

**Disposition:** Enacted

**Introduced:** 02/20/2015

**Status:** 08/19/2015 Signed by GOVERNOR.
08/19/2015 Public Act No. 403

**Sponsor:** Fine (D)

### IL H 3519

<table>
<thead>
<tr>
<th>Title: Pharmacy Practice Act</th>
</tr>
</thead>
</table>

**Summary:** Amends the Pharmacy Practice Act; provides that a pharmacist may substitute a biological product only if the product has been determined to be interchangeable, the physician does not designate that substitution is prohibited, the pharmacy informs the patient of the substitution, and the selected biological product that will be used as the substitution has a specified unit price;
<table>
<thead>
<tr>
<th>Title:</th>
<th>Insurance Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary:</td>
<td>Amends the Insurance Code; provides that insurers that issue individual and group accident and health policies that provides coverage for prescription drugs shall ensure that any required copayment or coinsurance applicable to drugs and rated as platinum, gold, or silver under federal regulations does not exceed $100 per month for up to a 30-day supply of any single drug, and $200 for plans rated as bronze level under federal regulations, and a beneficiary's annual out-of-pocket expenditures for.</td>
</tr>
<tr>
<td>Disposition:</td>
<td>Pending</td>
</tr>
<tr>
<td>Introduced:</td>
<td>02/26/2015</td>
</tr>
<tr>
<td>Status:</td>
<td>04/04/2016 From HOUSE Committee on RULES: Approved for consideration.</td>
</tr>
<tr>
<td>Commentary:</td>
<td>NORD submitted written testimony.</td>
</tr>
<tr>
<td>Sponsor:</td>
<td>Andrade (D)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title:</th>
<th>Rare Disease Commission Act</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary:</td>
<td>Creates the Rare Disease Commission Act; provides for the creation of the Rare Disease Commission; defines terms; provides that initial appointments shall be made by February 1, 2017; provides required criteria and considerations for appointees and nominations to the Commission; includes provisions regarding the terms, vacancies, and compensation for the Commission's membership; requires that the Commission meet at least quarterly and submit an annual report.</td>
</tr>
<tr>
<td>Disposition:</td>
<td>Pending</td>
</tr>
<tr>
<td>Introduced:</td>
<td>01/28/2016</td>
</tr>
<tr>
<td>Status:</td>
<td>04/13/2016 In SENATE. Placed on Calendar Order First Reading.</td>
</tr>
<tr>
<td>Commentary:</td>
<td>NORD and a coalition of rare advocates (including many of our Illinois-based member organizations) have strongly supported H 4676 and submitted letters and testimony to the House and Senate.</td>
</tr>
<tr>
<td>Sponsor:</td>
<td>Harper (D)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title:</th>
<th>Managed Care Reform and Patient Rights Act</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary:</td>
<td>Amends the Managed Care Reform and Patient Rights Act; applies the medical exemptions process to all entities licensed in the State to sell a policy of group or individual accident and health insurance or health benefits plan; provides certain exceptions upon</td>
</tr>
</tbody>
</table>
IL S 1359

Title: Insurance Code

Summary: Amends the Insurance Code; provides that a health plan that provides coverage for prescription drugs shall ensure that any required copayment or coinsurance applicable to drugs on a specialty tier does not exceed $100 per month for up to a 30-day supply of any single drug and a beneficiary's annual out-of-pocket expenditures for prescription drugs are limited to no more than fifty percent of the dollar amounts in effect under specified provisions of the federal Patient Protection Affordable Care Act.

Disposition: Pending - Carryover

Introduced: 02/18/2015

Status: 03/19/2015 In SENATE Committee on INSURANCE: To Subcommittee on Insurance Mandates and Special Issues.

Commentary: NORD supports this bill and submitted written testimony.

Sponsor: Holmes (D)

IL S 3037

Title: Managed Care Reform and Patient Rights Act

Summary: Amends the Managed Care Reform and Patient Rights Act; applies the medical exemptions process to all entities licensed in the State to sell a policy of group or individual accident and health insurance or health benefits plan; provides certain exceptions upon which a step therapy override will always be provided; sets clinical review criteria that must be used to establish step therapy protocols.

Disposition: Pending

Introduced: 02/18/2016

Status: 04/08/2016 In SENATE. Rule 2-10 Committee/3rd Reading Deadline Established As April 22, 2016.

Commentary: NORD supports this bill and submitted written testimony.

Sponsor: Morrison (D)

Indiana

IN S 41

Title: Pharmacy Benefits

Summary: Relates to pharmacy benefits; requires the State Employee Health Plan, an accident and sickness insurer, and a health maintenance organization to make available a procedure for a covered individual's use in requesting an exception to a step therapy protocol used by such entities with respect to coverage for certain prescription drugs, including time frames for a
determination concerning an exception and reasons for granting an exception.

**IN S 164**

- **Title:** Newborn Screening for Lysosomal Storage Disorders
- **Summary:** Adds the following lysosomal storage disorders to the newborn screening requirements: Krabbe disease; Pompe disease; Niemann-Pick disease; Gaucher disease; Fabry disease; Hurler syndrome.
- **Disposition:** Pending
- **Introduced:** 01/05/2016
- **Status:** 01/05/2016 INTRODUCED.
- **Commentary:** NORD supports this bill and submitted written testimony.
- **Author:** Miller Pa (R)

**IN SR 47**

- **Title:** State Department of Health Study
- **Summary:** Urges the state department of health to study the fiscal impact of additional newborn screening.
- **Disposition:** Adopted
- **Introduced:** 02/29/2016
- **Status:** 03/08/2016 Passed SENATE. (50-0)
- **Commentary:** NORD supports this bill and submitted written testimony.
- **Author:** Miller Pa (R)

**Kansas**

**KS H 2239**

- **Title:** Newborn Screening for Congenital Heart Disease
- **Summary:** Relates to newborn screening for critical congenital heart disease.
- **Disposition:** Pending - Carryover
- **Introduced:** 02/04/2015
- **Status:** 02/18/2015 Withdrawn from HOUSE Committee on HEALTH AND HUMAN SERVICES.
- **Commentary:** NORD supports this bill and submitted written testimony.
- **Author:** House Judiciary Committee
### KS S 341
- **Title:** Step Therapy for Medicaid Patients
- **Summary:** Allows step therapy for Medicaid patients; relates to the medical assistance program and the electronic claims management system; provides for a report detailing the amount of money saved.
- **Disposition:** Pending
- **Introduced:** 01/20/2016
- **Status:** 03/03/2016 House Hearing: 03/10/2016, 1:30PM Room 546-S
- **Commentary:** NORD supports this bill and submitted written testimony.
- **Author:** Senate Public Health and Welfare Committee

### KY S 134
- **Title:** Biological Products
- **Summary:** Defines biological product and interchangeable biological product and to re-order other definitions; requires lower-priced biological products to be dispensed when appropriate unless notified otherwise and require labeling and notification of biological product substitutions; adds biological products to inspection requirements.
- **Disposition:** Enacted
- **Introduced:** 01/28/2016
- **Status:** 04/09/2016 Signed by GOVERNOR. 04/11/2016 Act No. 73
- **Commentary:** NORD supports this bill and submitted written testimony.
- **Sponsor:** Alvarado (R)

### LA SCR 3
- **Title:** Newborn Screening
- **Summary:** Directs the Department of Health and Hospitals to submit a report on the health benefits and health care costs of adding Adrenoleukodystrophy (ALD) to the newborn screening panel; provides that the costs reported on shall include costs to the state lab operated through the Office of Public Health and also include a detailed financial analysis of how those costs would be reimbursed by Medicaid and to the extent determinable, by commercial insurance.
- **Disposition:** Pending
- **Introduced:** 03/14/2016
- **Status:** 04/06/2016 To HOUSE Committee on HEALTH AND WELFARE.
- **Author:** Mills (R)

### Massachusetts
<table>
<thead>
<tr>
<th>DOCKET</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1671</td>
<td>Prescription Drug Coverage and Step Therapy Protocols</td>
</tr>
<tr>
<td>2708</td>
<td>Substitution of Interchangeable Biosimilars</td>
</tr>
<tr>
<td>1977</td>
<td>Massachusetts Rare Disease Advisory Council</td>
</tr>
<tr>
<td>1967</td>
<td>Krabbe Disease in Newborn Screening</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relates to requiring certain requirements and restrictions for prescription drugs coverage and step-therapy protocols.</td>
</tr>
<tr>
<td>Relates to the substitution of interchangeable biosimilars.</td>
</tr>
<tr>
<td>Creates a Massachusetts Rare Disease Advisory Council.</td>
</tr>
<tr>
<td>Includes Krabbe disease in newborn screening.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pending</td>
</tr>
<tr>
<td>Pending - Carryover</td>
</tr>
<tr>
<td>Pending - Carryover</td>
</tr>
<tr>
<td>Pending - Carryover</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Introduced</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/11/2015</td>
</tr>
<tr>
<td>03/11/2015</td>
</tr>
<tr>
<td>03/11/2015</td>
</tr>
<tr>
<td>03/11/2015</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/16/2016 From JOINT Committee on FINANCIAL SERVICES: Ought to pass.</td>
</tr>
<tr>
<td>10/05/2015 Hearing scheduled for: 10/13/2015.</td>
</tr>
<tr>
<td>03/11/2015 Assigned HOUSE Bill No. 1977</td>
</tr>
<tr>
<td>03/11/2015 Assigned HOUSE Bill No. 1967</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benson (D)</td>
</tr>
<tr>
<td>Cusack (D)</td>
</tr>
<tr>
<td>Heroux (D)</td>
</tr>
<tr>
<td>Garry (D)</td>
</tr>
</tbody>
</table>

Commentary: NORD supports this bill and submitted written testimony.
DOCKET 1172
Title: Out of Pocket Expenses for Prescription Drug Coverage
Summary: Relates to out-of-pocket expenses for prescription drug coverage.
Disposition: Pending - Carryover
Introduced: 04/15/2015
Status: 11/17/2015 In JOINT Committee on FINANCIAL SERVICES: Heard. Eligible for Executive Session.
Commentary: NORD is a members of the Mass Patients for Prescription Access coalition. Our work on S 541 has included multiple rounds of legislative visits, 300 constituent generated emails, and in-person and written testimony. We are supporting the PFPA coalition in pursuing the bill as a budget amendment (A# 644 to H 4200).
Author: Petruccelli (D)

MA S 1145

DOCKET 1301
Title: Lysosomal Storage Disorders in Infants
Summary: Relates to Lysosomal Storage Disorders in infants.
Disposition: Pending
Introduced: 04/15/2015
Status: 03/28/2016 From JOINT Committee on PUBLIC HEALTH: Accompanied Study Order S 2199.
Commentary: NORD supports this bill and submitted written testimony.
Author: Fattman (R)

Maine

ME LR 586

Title: Screening of Newborns for Lysosomal Storage Disorders
Summary: Concerns screening of newborns for lysosomal storage disorders.
Disposition: Pending
Status: 01/14/2015 FILED.
01/14/2015 Assigned Senate Paper number 32 and LD 84.
Author: Senator Haskell

ME S 32

LD 84
Title: Screening of Newborns for Lysosomal Storage Disorders
Summary: Requires the Department of Health and Human Services to amend its rules in Chapter 283 by January 1, 2016 to add to the newborn screening program the lysosomal storage disorders known as Krabbe, Pompe, Gaucher, Fabry and Niemann-Pick diseases. It authorizes the department to explore options to enter into contracts with other states to test samples collected for lysosomal storage disorders.
### Michigan

**MI H 4812**

<table>
<thead>
<tr>
<th><strong>Title:</strong></th>
<th>Interchangeable Biological Drug Products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary:</strong></td>
<td>Provides the FDA-designated interchangeable biological drug products pharmacists are allowed to dispense.</td>
</tr>
<tr>
<td><strong>Disposition:</strong></td>
<td>Pending</td>
</tr>
<tr>
<td><strong>Introduced:</strong></td>
<td>08/18/2015</td>
</tr>
<tr>
<td><strong>Status:</strong></td>
<td>02/18/2016 From SENATE Committee on HEALTH POLICY: Recommended as substituted (S-1). (10-0)</td>
</tr>
<tr>
<td><strong>Commentary:</strong></td>
<td>H 4812 ensures that pharmacists communicate &quot;&quot; to a patient's prescribing physician &quot;&quot; any and all dispensations of a substitute biological product for another biologic drug. NORD supports this bill and submitted written testimony.</td>
</tr>
<tr>
<td><strong>Sponsor:</strong></td>
<td>Bizon (R)</td>
</tr>
</tbody>
</table>

### Minnesota

**MN S 693**

<table>
<thead>
<tr>
<th><strong>Title:</strong></th>
<th>Health</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary:</strong></td>
<td>Relates to health; adds a disorder to the lists of disorders to be tested for in the newborn screening program.</td>
</tr>
<tr>
<td><strong>Disposition:</strong></td>
<td>Pending - Carryover</td>
</tr>
<tr>
<td><strong>Introduced:</strong></td>
<td>02/06/2015</td>
</tr>
<tr>
<td><strong>Status:</strong></td>
<td>02/09/2015 To SENATE Committee on HEALTH, HUMAN SERVICES AND HOUSING.</td>
</tr>
<tr>
<td><strong>Author:</strong></td>
<td>Miller (R)</td>
</tr>
</tbody>
</table>
**Missouri**

### MO H 1366

**Title:** Laws Regarding Substitution By a Pharmacist  
**Summary:** Changes the laws regarding the substitution by a pharmacist of an interchangeable biological product for a prescribed product.  
**Disposition:** Pending  
**Introduced:** 01/06/2016  
**Status:** 04/18/2016 To SENATE Committee on GOVERNMENTAL ACCOUNTABILITY AND FISCAL OVERSIGHT  
**Commentary:** H 1366 ensures that pharmacists communicate "" to a patient’s prescribing physician "" any and all dispensations of a substitute biological product for another biologic drug. NORD supports this bill and submitted written testimony.  
**Sponsor:** Hubrecht (R)

### MO H 1387

**Title:** Newborn Screening Requirements  
**Summary:** Expands the newborn screening requirements to include severe combined immunodeficiency, also known as bubble boy disease.  
**Disposition:** Pending  
**Introduced:** 01/06/2016  
**Status:** 03/29/2016 To SENATE Committee on VETERANS' AFFAIRS AND HEALTH.  
**Commentary:** NORD supports this bill and submitted written testimony.  
**Sponsor:** Roeber (R)

### MO H 2029

**Title:** Step Therapy for Prescription Drugs  
**Summary:** Changes the laws regarding step therapy for prescription drugs; states that if coverage of a prescription drug for the treatment of any medical condition is restricted for use by a health carrier, health benefit plan, or utilization review organization via a step therapy protocol, the patient and prescribing practitioner shall have access to a readily accessible process to request a step therapy override exception determination.  
**Disposition:** Pending  
**Introduced:** 01/06/2016  
**Status:** 04/14/2016 In SENATE Committee on VETERANS' AFFAIRS AND HEALTH: Voted do pass.  
**Commentary:** NORD submitted written testimony  
**Sponsor:** Hoskins D (R)

---

**North Carolina**
**NC H 821**

**Title:** Proper Administration of Step Therapy Protocols

**Summary:** Ensures the proper administration of step therapy protocols for prescription drugs; defines clinical practice guidelines as a systematically developed statement to assist health care providers and patient decisions about appropriate health care for specific clinical circumstances and conditions; relates to written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by an insurer, health plan, or utilization review organization; relates to step therapy protocol.

**Disposition:** Failed - Adjourned

**Introduced:** 04/15/2015

**Status:** 04/30/2015 Withdrawn from calendar.

**Commentary:** 04/30/2015 Re-referred to HOUSE Committee on RULES, CALENDAR, AND OPERATIONS OF THE HOUSE.

**Author:** Lewis (R)

**Nebraska**

**NE L 979**

**Title:** Interchangeable Biological Products

**Summary:** Provides for selection of interchangeable biological products by pharmacists.

**Disposition:** Pending

**Introduced:** 01/14/2016

**Status:** 02/19/2016 From LEGISLATIVE Committee on HEALTH AND HUMAN SERVICES: Placed on General File as amended. (5-0)

**Author:** Kuehn (NP)

**New Hampshire**

**NH LSR 623**

**Title:** Krabbe Leukodystrophy Newborn Screening

**Summary:** Relates to newborn screening for Krabbe Leukodystrophy.

**Disposition:** Pending - Carryover

**Status:** 01/20/2015 Assigned Bill Number: S 200.

**Author:** Office of Sam Cataldo

**New Jersey**

**NJ A 817**

**Title:** Disorders in Newborn Screening Program

**Summary:** Expands number of disorders included in newborn screening program.
NJ A 3137

Title: Rare Disease Advisory Council
Summary: Establishes the New Jersey Rare Disease Advisory Council.

Disposition: Pending
Introduced: 02/22/2016
Status: 02/22/2016 INTRODUCED.
02/22/2016 To ASSEMBLY Committee on HEALTH AND SENIOR SERVICES.
Sponsor: Dancer (R)

NJ S 1283

Title: Newborn Screening Program
Summary: Revises Newborn Screening program in Department of Health.

Disposition: Pending
Introduced: 02/08/2016
Status: 02/08/2016 INTRODUCED.
02/08/2016 To SENATE Committee on HEALTH, HUMAN SERVICES AND SENIOR CITIZENS.
Sponsor: Vitale (D)

New York

NY A 5174

Title: Prescription Drug Coverage
Summary: Amends the Insurance Law; requires prescription drug coverage to include such supplements and vitamins, medical foods, and other medications as shall be deemed necessary to mitigate or treat the symptoms of mitochondrial disease.

Disposition: Pending
Introduced: 02/12/2015
Status: 01/19/2016 Amended in ASSEMBLY Committee on INSURANCE.
Commentary: NORD submitted written testimony
Sponsor: McDonald J (D)

NY S 3250
Title: Prescription Drug Coverage
Summary: Amends the Insurance Law; requires prescription drug coverage to include such supplements and vitamins, medical foods, and other medications as shall be deemed necessary to mitigate or treat the symptoms of mitochondrial disease; include coverage for the cost of such supplements and vitamins, medical foods, and other medications; includes coverage may be subject to such annual deductibles and coinsurance.

Disposition: Pending
Introduced: 02/03/2015
Status: 01/15/2016 Amended in SENATE Committee on INSURANCE.
Commentary: NORD submitted written testimony
Sponsor: Little (R)

NY S 6311
Title: Interchangeable Biological Products
Summary: Relates to interchangeable biological products; enacts provisions relating to substitutions of biological products by pharmacists.
Disposition: Pending
Introduced: 01/06/2016
Status: 01/06/2016 INTRODUCED.
01/06/2016 To SENATE Committee on HEALTH.
Sponsor: Hannon (R)

Ohio
OH H 505
Title: Regulation of Biological Products
Summary: Regards the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
Disposition: Pending
Introduced: 04/04/2016
Status: 04/13/2016 From HOUSE Committee on RULES AND REFERENCE: Recommended referral.
04/13/2016 In HOUSE. To second reading. Read a second time.
04/13/2016 To HOUSE Committee on HEALTH AND AGING.
Commentary: NORD submitted written testimony
Sponsor: Huffman S (R)

OH S 14
Title: Krabbe Disease Newborn Screening
Summary: Requires that Krabbe disease be included in the Newborn Screening Program.
Disposition: Pending - Carryover
**OH S 135**

**Title:** Rare Disease Drug Health Care Coverage  
**Summary:** Limits the out-of-pocket cost to an individual covered by a health plan for drugs used to treat rare diseases.  
**Disposition:** Pending - Carryover  
**Introduced:** 03/25/2015  
**Status:** 04/14/2015 From SENATE Committee on RULES AND REFERENCE: Recommended referral.  
04/14/2015 In SENATE. To second reading. Read a second time.  
04/14/2015 To SENATE Committee on INSURANCE.  
**Commentary:** NORD is a member of the Ohio Out-of-Pocket coalition.  
**Sponsor:** Cafaro (D)

**OH S 243**

**Title:** Step Therapy Protocols  
**Summary:** Adopts requirements related to step therapy protocols implemented by health plan issuers and the Department of Medicaid; provides for clinical review criteria, utilization review organizations, rate filing documents, public information and electronic insurance records.  
**Disposition:** Pending - Carryover  
**Introduced:** 11/17/2015  
**Status:** 12/09/2015 From SENATE Committee on RULES AND REFERENCE: Recommended referral.  
12/09/2015 In SENATE. To second reading. Read a second time.  
12/09/2015 To SENATE Committee on MEDICAID.  
**Sponsor:** Lehner (R)

**Oklahoma**

**OK H 1503**

**Title:** Pharmacies  
**Summary:** Relates to pharmacies; defines certain terms; permits pharmacists to dispense substitute biological product under certain conditions; requires State Board of Pharmacy to maintain certain list on its website; provides for codification; provides an effective date.  
**Disposition:** Pending - Carryover  
**Introduced:** 02/02/2015
OK H 1504
Title: Insurance
Summary: Relates to insurance; defines terms; limits certain copayments and costs for certain prescription and specialty drugs; requires certain health plans to implement an exceptions process; provides that certain denials shall be subject to certain external review; prohibits certain health plan from placing certain drugs on a specialty tier; requires the Insurance Commissioner to promulgate certain rules; construes provisions; provides for codification; provides an effective date.
Disposition: Pending - Carryover
Introduced: 02/02/2015
Status: 02/03/2015 To HOUSE Committee on INSURANCE.
Author: Virgin (D)

OK H 2607
Title: Education and Newborn Screening Program
Summary: Relates to public safety; relates to an education and newborn screening program; requires State Board of Health to expand program to include adrenoleukodystrophy; provides an effective date.
Disposition: Pending
Introduced: 02/01/2016
Status: 02/02/2016 To HOUSE Committee on APPROPRIATIONS AND BUDGET.
Author: McDaniel J (D)

OR H 4105
Title: Biological Product Dispenses
Summary: Requires a pharmacy or pharmacist that dispenses a biological product to communication the specific product dispensed to the patient, including the name and manufacturer of the product, by making an entry into an electronic system that the prescribing practitioner can access electronically that meets specified requirements; provides others methods of communicating with the practitioner.
Disposition: Enacted
Introduced: 02/01/2016
Status: 03/14/2016 Chaptered. Chapter No. 43
Commentary: NORD supports this bill and submitted written testimony.
Author: House Health Care Committee
### Pennsylvania

#### PA S 514
- **PN**: 509
- **Title**: Powers and Duties of the Department of Health
- **Summary**: Amends the act of November 24, 1976 (P.L.1163, No.259), referred to as the Generic Equivalent Drug Law; provides for definitions, for substitutions, for posting requirements, for powers and duties of Department of Health and for immunity of pharmacists under certain circumstances.
- **Disposition**: Pending - Carryover
- **Introduced**: 02/19/2015
- **Status**: 05/14/2015 To HOUSE Committee on HEALTH.
- **Author**: Vance (R)

#### PA S 841
- **PN**: 963
- **Title**: Requirements for Insurers and Prescription Drugs
- **Summary**: Provides requirements for insurers relating to prescription drug coverage; confers powers and imposing duties on the Insurance Department.
- **Disposition**: Pending - Carryover
- **Introduced**: 05/28/2015
- **Status**: 05/28/2015 FILED.
  - 05/28/2015 INTRODUCED.
  - 05/28/2015 To SENATE Committee on BANKING AND INSURANCE.
- **Commentary**: NORD submitted written testimony and conducted legislative visits as part of our Rare Disease Day event. NORD is a member of Medication Access Pennsylvania.
- **Author**: Mensch (R)

### Rhode Island

#### RI H 7816
- **Title**: Pharmacy Dispensed Biological Product Regulation
- **Summary**: Would add biological products and interchangeable biological products to the medications pharmacies may dispense, and would regulate the procedures for dispensing and substitution. This act would take effect upon passage.
- **Disposition**: Pending
- **Introduced**: 03/02/2016
- **Status**: 04/06/2016 In HOUSE Committee on HEALTH, EDUCATION AND WELFARE: Committee recommends measure to be held for further study.
- **Author**: Serpa (D)
**TN H 33**

**Title:** Health Care

**Summary:** Relates to Health Care; requires that every newborn be tested for lysosomal storage disorders, including Krabbe, Fabry, Gaucher, Pompe, Hurler Syndrome, Niemann-Pick, and others as determined by the department of health as screenings for such become available.

**Disposition:** Pending - Carryover

**Introduced:** 01/14/2015

**Status:** 04/21/2015 From HOUSE Committee on FINANCE, WAYS AND MEANS: Recommend passage with amendment. 04/21/2015 To HOUSE Committee on CALENDAR AND RULES. 04/21/2015 Placed on Regular Calendar. 04/22/2015 In HOUSE. Substituted on HOUSE floor by S 44

**Author:** Dunn (R)

---

**TN S 44**

**Title:** Lysosomal Storage Disorder Newborn Testing

**Summary:** Requires that every newborn be tested for lysosomal storage disorders, including Krabbe, Fabry, Gaucher, Pompe, Hurler Syndrome, Niemann-Pick, and other genetic, metabolic, or other heritable conditions; provides for fees.

**Disposition:** Enacted

**Introduced:** 01/14/2015

**Status:** 05/20/2015 Public Chaptered. Chapter No. 436

**Author:** Massey (R)

---

**TN S 2084**

**Title:** Pediatric Rare Disease Treatment Information Act

**Summary:** Relates to Children; enacts the Access to Pediatric Rare Disease Treatment Information Act; provides for sharing of essential treatment information for children with cancer among certain health care institutions.

**Disposition:** Pending

**Introduced:** 01/21/2016

**Status:** 03/16/2016 In SENATE Committee on GOVERNMENT OPERATIONS: Referred to General Subcommittee.

**Author:** Overbey (R)

---

**Virginia**

**VA H 362**

**Title:** Step Therapy Protocols

**Summary:** Relates to step therapy protocols; relates to disclosures; requires health insurers that limit coverage for prescription drugs through
the use of a step therapy protocol to have in place a process for a prescribing provider to request an override of the protocol for a patient.

**Disposition:** Pending - Carryover  
**Introduced:** 01/13/2016  
**Status:** 02/02/2016 In HOUSE Committee on COMMERCE AND LABOR: Continued to 2017.  
**Author:** Davis (R)

### Wisconsin

#### WI S 39

**Title:** Newborn Screening  
**Summary:** Relates to newborn screening for certain lysosomal storage disorders.  
**Disposition:** Failed  
**Introduced:** 02/19/2015  
**Status:** 04/13/2016 Failed to pass pursuant to Senate Joint Resolution 1.  
**Author:** Lassa (D)